尼莫地平为钙通道桔抗剂，主要用于防治缺血性脑血管疾病，但该药为脂溶性，难溶于水。口服片剂生物利用度低，仅为静脉注射的3％～28％[1.2]，很难达到药物应有的疗效。近年来，国内有应用固体分散技术，改善尼莫地平的溶出度，提高其生物利用度的报道[3]，目前国内有5个生产 Nimodipine is a calcium channel antagonist, mainly for the prevention and treatment of ischemic cerebrovascular disease, but the drug is fat-soluble, insoluble in water. Oral tablet bioavailability is low, only 3% to 28% of intravenous injection [1.2], it is difficult to achieve the desired effect of the drug. In recent years, the domestic application of solid dispersion technology to improve the dissolution of nimodipine to improve its bioavailability reported [3], at present there are 5 production